Vericel Announces FDA Approval and Commercial Availability of MACI Arthro
First Restorative Biologic Cartilage Repair Product Approved for Arthroscopic Administration
Targets the Largest Segment of MACI’s $3 Billion Addressable Market
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care, has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) that expands the MACI (autologous cultured chondrocytes on porcine collagen membrane) label. This new approval allows for the arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects in the knee, covering areas up to 4 cm2. The introduction of MACI Arthro offers a less invasive alternative to traditional methods, enabling surgeons to assess and prepare the defect site more efficiently while using smaller incisions and specially designed instruments.
“The approval of MACI Arthro marks a significant milestone in our dedication to providing innovative solutions for patients with cartilage defects in the knee,” stated Nick Colangelo, President and CEO of Vericel. “This less invasive option not only improves patient care but also aims to significantly increase our share of the MACI addressable market, supporting sustained revenue growth for the Company in the coming years.”
MACI is recognized as the first FDA-approved cellularized scaffold product that employs tissue engineering processes to cultivate cells on scaffolds derived from the patient's healthy cartilage. The MACI Arthro offers orthopedic surgeons a beneficial arthroscopic approach without compromising the established clinical outcomes and durability associated with MACI. The specialized MACI Arthro instruments are designed to focus on common cartilage defects in the market, particularly 2-4 cm2 defects on the femoral condyles, which could potentially benefit around 20,000 patients each year. This number represents about one-third of the $3 billion addressable market linked to MACI. Additionally, Vericel plans to expand its target surgeon base from 5,000 to 7,000 professionals who perform high-volume cartilage repair surgeries, primarily through arthroscopic techniques.
“The arthroscopic technique for delivering MACI is a major advancement in cartilage repair,” commented Grant H. Garcia, MD, Orthopedic Specialists of Seattle. “With MACI Arthro, surgeons can provide patients with a clinically-proven treatment that offers enhanced post-operative benefits compared to traditional open surgery.”
Understanding MACI Technology
About MACI
MACI (autologous cultured chondrocytes on porcine collagen membrane) is a personalized cellular scaffold product specifically designed for repairing symptomatic single or multiple full-thickness cartilage defects in the knee, regardless of bone involvement, in adults. The MACI implant consists of autologous cultured chondrocytes that are seeded onto a resorbable Type I/III collagen membrane, sourced directly from the patient's own cartilage, making it a tailored treatment option.
MACI is the only restorative biologic cartilage repair product currently approved for arthroscopic techniques. The innovative approach of MACI Arthro is expected to combine the benefits of minimally invasive surgical options with the consistent durability and proven clinical success associated with MACI.
Market Expansion Strategies
Following the launch of MACI Arthro, Vericel's strategy for expansion involves broadening their target surgeon demographic to reach more orthopedic specialists known for performing high volumes of cartilage repair treatments. By providing these surgeons with the necessary tools and training to implement MACI Arthro, Vericel aims to strengthen its position in the cartilage repair market.
This initiative is expected to not only boost product adoption but also positively impact the quality of patient care throughout the orthopedic field. This strategic move is crucial for ensuring that Vericel continues to rise within the competitive landscape of advanced medical therapies for cartilage repair.
Safety Information for MACI
Important Safety Information
As with any medical product, MACI has certain limitations and precautions. It is contraindicated for patients with known hypersensitivity to any of its components or for those who have had knee surgery within the past six months, excluding biopsies. The effectiveness of MACI for joints other than the knee has not been established, and it should only be used as directed for knee-related cartilage defects.
Patients should also be made aware of the risks associated with the procedure, which may include adverse reactions such as arthralgia and joint swelling.
It is essential for patients considering MACI treatment to discuss their medical history with their healthcare providers to ensure safe and effective use.
About Vericel Corporation
Vericel is a leading provider of innovative therapies focused on sports medicine and severe burn care. The company combines biological innovations with advanced medical technologies, offering a diverse portfolio that includes three marketed products in the United States: MACI for cartilage repair, Epicel (cultured epidermal autografts) for skin replacements, and NexoBrid (used for eschar removal).
Vericel's commitment to advancing patient care through groundbreaking therapies uniquely positions it in its field, contributing to improved recovery experiences and outcomes for patients suffering from debilitating injuries.
Frequently Asked Questions
What is MACI Arthro?
MACI Arthro is an FDA-approved cartilage repair product that allows for less invasive arthroscopic delivery of MACI to treat symptomatic knee cartilage defects.
What markets does MACI target?
MACI primarily targets the knee cartilage repair market, which is estimated to have a $3 billion addressable market.
Who can benefit from MACI?
Adults with symptomatic single or multiple full-thickness cartilage defects of the knee can benefit from MACI treatment.
What are the key benefits of using MACI Arthro?
The use of MACI Arthro offers a less invasive surgical option with the advantages of long-term durability and established clinical results.
How can I contact Vericel Corporation for more information?
For inquiries, you can reach out to Vericel Corporation at 1-800-453-6948 or via email at ir@vcel.com.
